Virbac SA (PA:VIRP) — Market Cap & Net Worth
Market Cap & Net Worth: Virbac SA (VIRP)
Virbac SA (PA:VIRP) has a market capitalization of $3.01 Billion (€2.58 Billion) as of September 21, 2026. Listed on the PA stock exchange, this France-based company holds position #4939 globally and #83 in its home market, demonstrating a 2.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Virbac SA's stock price €310.50 by its total outstanding shares 8377824 (8.38 Million). Also see Virbac SA assets under control for a full breakdown of the balance sheet.
Virbac SA Market Cap History: 2015 to 2026
Virbac SA's market capitalization history from 2015 to 2026. Data shows growth from $2.12 Billion to $3.04 Billion (5.37% CAGR). Also see Virbac SA operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Virbac SA is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid 60
CACMD
|
$189.60 Billion | 1.59% | #21 of 55 |
|
CAC Mid & Small
CACMS
|
$226.34 Billion | 1.33% | #22 of 119 |
|
CAC All-Tradable
CACT
|
$2.81 Trillion | 0.11% | #75 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.81 Trillion | 0.11% | #75 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.81 Trillion | 0.11% | #75 of 179 |
|
CAC PME
CAPME
|
$41.14 Billion | 7.32% | #5 of 34 |
|
CAC Health Care
FRHC
|
$239.52 Billion | 1.26% | #8 of 36 |
Weight: Virbac SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Virbac SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Virbac SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Virbac SA share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.22x
Virbac SA's market cap is 2.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
21.34x
Virbac SA's market cap is 21.34 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.12 Billion | $852.62 Million | $9.40 Million | 2.49x | 225.53x |
| 2016 | $1.61 Billion | $871.83 Million | $34.65 Million | 1.85x | 46.57x |
| 2017 | $1.19 Billion | $861.88 Million | -$2.58 Million | 1.38x | N/A |
| 2018 | $1.10 Billion | $868.93 Million | $20.10 Million | 1.26x | 54.64x |
| 2019 | $2.28 Billion | $938.34 Million | $51.55 Million | 2.43x | 44.27x |
| 2020 | $2.30 Billion | $934.20 Million | $136.04 Million | 2.46x | 16.88x |
| 2021 | $4.11 Billion | $1.06 Billion | $113.16 Million | 3.86x | 36.30x |
| 2022 | $2.21 Billion | $1.22 Billion | $121.97 Million | 1.82x | 18.15x |
| 2023 | $3.51 Billion | $1.25 Billion | $121.30 Million | 2.81x | 28.92x |
| 2024 | $3.10 Billion | $1.40 Billion | $145.29 Million | 2.22x | 21.34x |
Competitor Companies of VIRP by Market Capitalization
Companies near Virbac SA in the global market cap rankings as of September 21, 2026. Review Virbac SA (VIRP) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Virbac SA by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $1.03 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #45 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $1.03 Trillion | $1152.93 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $269.99 |
| #45 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $263.96 |
Virbac SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Virbac SA's market cap moved from $2.12 Billion to $ 3.04 Billion, with a yearly change of 5.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.04 Billion | -13.15% |
| 2025 | €3.50 Billion | +12.95% |
| 2024 | €3.10 Billion | -11.63% |
| 2023 | €3.51 Billion | +58.43% |
| 2022 | €2.21 Billion | -46.10% |
| 2021 | €4.11 Billion | +78.84% |
| 2020 | €2.30 Billion | +0.63% |
| 2019 | €2.28 Billion | +107.82% |
| 2018 | €1.10 Billion | -7.85% |
| 2017 | €1.19 Billion | -26.14% |
| 2016 | €1.61 Billion | -23.93% |
| 2015 | €2.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Virbac SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.01 Billion USD |
| MoneyControl | $3.01 Billion USD |
| MarketWatch | $3.01 Billion USD |
| marketcap.company | $3.01 Billion USD |
| Reuters | $3.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. I… Read more